Tesamorelin vs Ipamorelin: What the Research Shows
Tesamorelin and Ipamorelin side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Tesamorelin if…
- you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[5]
- you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[15]
Consider Ipamorelin if…
- you want the option with a randomized human trial, though it found no significant difference from placebo (postoperative ileus): median time to first tolerated meal was 25.3 h vs 32.6 h[12]
What they have in common
Spec comparison
Showing 8 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.
| Field | Tesamorelin | Ipamorelin |
|---|---|---|
| Class | GHRH analog | GHRP (ghrelin receptor agonist) |
| Also called | tesa, Egrifta | ipa, ipam |
| Category | Growth hormone | Growth hormone |
| FDA status | FDA approved (Egrifta) | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. | Prohibited by WADA (S2.2.4)Ipamorelin is named as a growth hormone secretagogue in S2.2.4, prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) | 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 | Human RCT evidence, 4 of 4Strongest: International journal of colorectal disease 2014, PMID 25331030 |
| Human studies we summarised | 12 human (11 randomized or controlled) of 16 summarised | 2 human (2 randomized or controlled) of 12 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 2 mg, 5 mg, 10 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Yes (24 Aug 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Sold mixed: Tesamorelin + Ipamorelin
These blends put both in one vial. The blend calculator works out the dose of each component per draw. Evidence for the combination: No studies tested these together (PubMed search: 6 results, 2 Oct 2026).
A releasing-hormone analogue versus a ghrelin-pathway peptide
Tesamorelin has phase 3 data on abdominal fat in HIV and on liver fat; ipamorelin has no trial on fat of any kind in people.[7]
Ipamorelin's only patient trial tested recovery of gut function after bowel surgery; the median time to a tolerated meal was not significantly shorter than on placebo.[12]
In rats, ipamorelin increased body weight and bone measures, but these are animal results with no counterpart in human fat or muscle.[16]
Tesamorelin's human data even include muscle: a secondary analysis found area and density improved in those whose visceral fat fell.[8]
Both raise GH, but tesamorelin's effect on IGF-I was measured over months and was large, while ipamorelin's GH peak was a single brief pulse.[11]
Safety notes, label status and sport
Tesamorelin is the only one with a US label, for HIV-associated abdominal fat, and it states it is not for weight loss.[5]
FDA's review of compounded ipamorelin cites death in a study of intravenous use for gut motility, a signal absent from the tesamorelin label.[17]
Tesamorelin's label warns of fluid retention that may include swelling, joint pain and carpal tunnel syndrome.[5]
The two share a prohibited-list section, tesamorelin as a GHRH analogue and ipamorelin as a secretagogue.[2]
Ipamorelin has a measured half-life of a couple of hours in healthy men, while tesamorelin's label gives it in minutes.[11]
Common questions
Is tesamorelin better than ipamorelin?
Tesamorelin has randomised trials and an approved label; ipamorelin's only patient trial missed its efficacy endpoints.[12]
Which is better for belly fat, tesamorelin or ipamorelin?
Only tesamorelin has human evidence on abdominal fat, in HIV-associated lipodystrophy, with a label that excludes general weight loss.[15]
Can you take tesamorelin and ipamorelin together?
No study tests the pair, and both appear on the prohibited list.[2]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 9Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 10Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 11Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 12Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 13The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
- 14PubMed search: (ipamorelin[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 16The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.The Journal of endocrinology · 2000PMID 10828840Accessed 2 Oct 2026
- 17Official web pageOfficial web page · web page
Found an error? Report a correction.